The DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
Abstract
Background Pegbelfermin (BMS-986036), a PEGylated human fibroblast growth factor 21 (FGF21) analogue, has previously been shown to improve markers of metabolism and liver fibrosis in obese patients with type 2 diabetes. In this phase 2a study, we aimed to evaluate the safety and efficacy of pegbelfermin in patients with non-alcoholic steatohepatitis.Methods In this multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2a study, we recruited adults (aged 21-75 years) with a body-mass index of at least 25 kg/m 2, biopsy-confirmed non-alcoholic steatohepatitis (fibrosis stage 1-3), and a hepatic fat fraction of at least 10% when assessed by magnetic resonance imaging-proton density fat fraction. These patients were enrolled at 17 medical centres in the USA. Eligible patients were stratified by type 2 diabetes status and they were randomly assigned (1:1:1) by a computer-based system to receive subcutaneous injections of placebo once a day, 10 mg pegbelfermin once a day, or 20 mg pegbelfermin once a week, all for 16 weeks. Participants, the study team administering treatment, and investigators analysing outcomes (who were independent of the study team and had no further involvement) were masked to treatment groups. The primary outcomes were safety and the absolute change in hepatic fat fraction after 16 weeks of treatment. All patients who were randomly assigned to groups and received the study drug or placebo were included in the primary analyses. This trial was registered with ClinicalTrials.gov, number NCT02413372.Findings Between May 12, 2015, and Aug 4, 2016, 184 overweight or obese patients with non-alcoholic steatohepatitis were screened for study inclusion. Of these, 95 (52%) patients were excluded because they no longer met study criteria and 80 (43%) patients entered the placebo lead-in phase. After further exclusions, 75 (94%) patients were randomly assigned to groups, received at least one dose of treatment (25 patients to receive 10 mg pegbelfermin once a day; 24 patients to receive 20 mg pegbelfermin once a week, and 26 patients to receive placebo), and were included in the primary analysis. A prespecified interim analysis at week 8 showed a greater than expected change in the primary outcome and supported early closing of patient enrolment, since this analysis indicated that the full planned sample size was not needed. We observed a significant decrease in absolute hepatic fat fraction in the group receiving 10 mg pegbelfermin daily (-6·8% vs -1·3%; p=0·0004) and in the group receiving 20 mg pegbelfermin weekly (-5·2% vs -1·3%; p=0·008) compared with the placebo group. Most adverse events were mild; the most common events were diarrhoea in eight (16%) of 49 patients treated with pegbelfermin and two (8%) of 26 patients treated with placebo and nausea in seven (14%) patients treated with pegbelfermin and two (8%) patients treated with placebo. There were no deaths, discontinuations due to adverse events, or treatment-related serious adverse events.Interpretation Treatment with subcutaneously administered pegbelfermin for 16 weeks was generally well tolerated and significantly reduced hepatic fat fraction in patients with non-alcoholic steatohepatitis. Further study of pegbelfermin is warranted in patients with non-alcoholic steatohepatitis. Additional studies that use liver biopsies would allow for the assessment of pegbelfermin's effects on liver histology. Moreover, further studies should allow assessments of the safety and effectiveness of pegbelfermin in a larger number of patients.Funding Bristol-Myers Squibb.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Pegbelfermin showed a reduction in hepatic fat (measured via MRI‐PDFF) and liver transaminases over a 16‐week treatment period as well as an improved lipid profile; [53] however, no histological readouts were available which hampers applicability of the results and warrants further studies on this compound.”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [53]
In the citing paper
“Pegbelfermin showed a reduction in hepatic fat (measured via MRI‐PDFF) and liver transaminases over a 16‐week treatment period as well as an improved lipid profile; [53] however, no histological readouts were available which hampers applicability of the results and warrants further studies on this compound.”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [53]
In the citing paper
“all analogues consistently have a pronounced ability to decrease plasma triglyceride levels, in many cases by as much as ~70% (refs. 81,87–91).”
From Metabolic messengers: FGF21 (2021) · cites this paper as [89]
In the citing paper
“two other FGF21 analogues, AKR-001 (also known as efruxifermin)88 and pegbelfermin89,90, have not been found to significantly decrease body weight in people with obesity or type 2 diabetes.”
From Metabolic messengers: FGF21 (2021) · cites this paper as [89]
In the citing paper
“the magnitude of the glucose-lowering effects of FGF21 analogues is clearly lower in humans than rodents81,87–91, perhaps because of differences in brown adipose tissue metabolism between species65.”
From Metabolic messengers: FGF21 (2021) · cites this paper as [89]
In the citing paper
“Administration of the FGF21 analogues AKR-001 (ref. 88) and pegbelfermin89 in humans with NASH results in marked absolute decreases in liver fat (up to 70%) and significant amelioration of liver fibrosis88,89.”
From Metabolic messengers: FGF21 (2021) · cites this paper as [89]
In the citing paper
“clinical studies in patients with obesity and type 2 diabetes have found that FGF21-analogue administration markedly induces plasma adiponectin levels81,87–89”
From Metabolic messengers: FGF21 (2021) · cites this paper as [89]
In the citing paper
“PF-05231023 has been found to increase markers of bone turnover in humans81, whereas AKR-001 (ref. 88) and pegbelfermin89 have not.”
From Metabolic messengers: FGF21 (2021) · cites this paper as [89]
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationYounossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citationBedogni, G., Bellentani, S., Miglioli, L., Masutti, F., Passalacqua, M., Castiglione, A., & Tiribelli, C. (2006) · BMC Gastroenterology · doi:10.1186/1471-230x-6-33 · Cited by 3,146
Classification and Diagnosis of Diabetes
Fajans, S. S. (1990) · Medical Entomology and Zoology · Cited by 2,356
Nonalcoholic Fatty Liver Disease
Rinella, M. E. (2015) · JAMA · doi:10.1001/jama.2015.5370 · Cited by 2,320
The Fibroblast Growth Factor signaling pathway
Ornitz, D. M., & Itoh, N. (2015) · WIREs Developmental Biology · doi:10.1002/wdev.176 · Cited by 2,050
Xu, A., Wang, Y., Keshaw, H., Xu, L. Y., Lam, K. S. L., & Cooper, G. J. S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17797 · Cited by 1,312
Xu, A., Wang, Y., Keshaw, H., Xu, L. Y., Lam, K. S. L., & Cooper, G. J. S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317797 · Cited by 1,298
Hagström, H., Nasr, P., Ekstedt, M., Hammar, U., Stål, P., Hultcrantz, R., & Kechagias, S. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.07.027 · Cited by 1,067
Research works printed but not linked: 3
- Charles, 2016, A phase 1 study of BMS-986036 (pegylated FGF21) in healthy obese subjects, Hepatology, 64, 546A
- Krupinski, 2016, Effects of BMS-986036 (pegylated fibroblast growth factor 21) on hepatic steatosis and fibrosis in a mouse model of nonalcoholic steatohepatitis, Hepatology, 64, 749A
- Leeming DJ, Nielsen MJ, Goodman Z, et al. Plasma collagen III type III (Pro-C3) levels associate with severity of histological features of non-alcoholic steatohepatitis and fibrosis within the screening population from the CENTAUR study. NASH Biomarkers Workshop; Washington, DC, USA; May 5, 2017.
Cited by
Sorted by citations
Items 501–549 of 549
Muzica, C. M., Trifan, A. V., Zenovia, S., Gîrleanu, I., Cojocariu, C., & Stanciu, C. (2023) · Springer eBooks · doi:10.1007/978-3-031-33548-8_21
Endocrinopathies in Nonalcoholic Fatty Liver Disease
Sîngeap, A.-M., & Huiban, L. (2023) · Springer eBooks · doi:10.1007/978-3-031-33548-8_16
An Overview of Bone Toxicology
Doyle, N., Bédard, A., Schafbuch, R. M., Boyd, G., Felx, M., White, J. R., & Varela, A. (2023) · Springer eBooks · doi:10.1007/978-3-030-73317-9_119-1
Li, X. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15793-6.00000-7
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-4473-0
Suzuki, M., Hayashi, T., Nashiki, K., Kawata, H., Nagata, S., & Abe, T. (2024) · Radiological Physics and Technology · doi:10.1007/s12194-024-00811-z
Bond, S. T., King, E. J., Walker, S., Yang, C., Liu, Y., Liu, K. H., Zhuang, A., Jurrjens, A. W., Fang, H., Formosa, L. E., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.02.597064
Patt, M., Karkossa, I., Krieg, L., Massier, L., Makki, K., Tabei, S., Karlas, T., Dietrich, A., Gericke, M. T., Stümvoll, M., et al. (2024) · medRxiv · doi:10.1101/2024.05.31.24307065
Endocrine fibroblast growth factors in domestic animals
Brinker, E. J., Hardcastle, M., Dittmer, K. E., & Graff, E. C. (2024) · Domestic Animal Endocrinology · doi:10.1016/j.domaniend.2024.106872
Mirhoseini, M., Eslamian, G., Ghorbani, A., Zand, H., & Vasheghani‐Farahani, E. (2024) · Iṭṭilā’āt-i māhiyānah. · doi:10.61186/nsft.19.2.1
O RASTREAMENTO DA ESTEATOSE HEPÁTICA NO DIABETES MELLITUS TIPO 2
da Silva, M. C., Carneiro, C. G., Vieira, L. M., França, M. K., Cerqueira, P. A. S., & Ferraz, A. R. (2024) · Revista Ibero-Americana de Humanidades, Ciências e Educação · doi:10.51891/rease.v10i9.15467
An Overview of Bone Toxicology
Doyle, N., Bédard, A., Schafbuch, R. M., Boyd, G., Felx, M., White, J. R., & Varela, A. (2024) · Springer eBooks · doi:10.1007/978-3-031-35529-5_119
Shahzil, M., Hasan, F., Kazmi, S. K., Gangwani, M. K., Shabbar, U.-E.-S., Chaudhary, A. J., Khaqan, M. A., Faisal, M. S., Williams, K. N., Mohan, B. P., et al. (2025) · JGH Open · doi:10.1002/jgh3.70131
The Role of Nuclear Receptor PPAR in Liver Fibrosis
思, 璐. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.1541071
Sobral, M. V. S., Faria, H. S., Bendaham, L. C. A. R., Masiero, B. B., Gouvêa, C. A., Faria, G. D. S., dos Santos, M. D., Peres, C. D. A. P., de Oliveira, L. M., & Souto, E. B. (2025) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001868
de Souza, M. H. G., Al‐Sharif, L., Khalil, S. M., & Diaz, I. (2025) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2025.103173
Pharmacologic intervention of nonalcoholic steatohepatitis and related cirrhosis
Zeb, A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27370-4.00023-8
Strużek, K., Kwiatkowska, A., Mączka, E., Tracz, W., Świercz, P., Teper, K., Khiralla-Gawlik, S., Strzelecka, A. A., & Basak, A. E. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3662
The value of fibroblast growth factor 21 in health and pathology
Akhverdyan, Y., Papichev, E., Zavodovsky, B. V., Polyakova, Y. V., Seewordova, L. E., & Сергеевна, Р. Е. (2025) · Сибирский журнал клинической и экспериментальной медицины · doi:10.29001/2073-8552-2025-40-3-28-35
van Zutphen, T., Struik, D., Liu, W., Liu, S., Sermikli, B. P., Wolters, J. C., Verkade, H. J., Atkins, A. R., Downes, M., Evans, R. M., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101660
Liu, L., Ning, N., Xu, S., Chen, D., Zhou, L., Guo, Z., Liang, X., & Ye, X. (2024) · Figshare · doi:10.6084/m9.figshare.26733019
Wulff, A. B., Varbo, A., Nordestgaard, A. G., & Nordestgaard, B. G. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2639678 · Cited by 2
Lin, J., Jin, G., Zhang, L., Weng, X., & Wu, K. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05195-y
Drugging cold-response networks for neuroprotection
Zhang, M., Liu, C., Cheng, A., & Li, M. (2026) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2026.02.003 · Cited by 1
Rôle des FGFs endocrines et leurs récepteurs au cours de la fibrose pulmonaire idiopathique
Ghanem, M. (2023) · theses.fr (ABES) · doi:10.70675/fd0d64f8zacf4z4856z9b1az66d4df37a332
Inter-organ communication in physiology and pathophysiology : a role for the ChREBP-FGF21 axis?
Carbinatti, T. (2024) · theses.fr (ABES) · doi:10.70675/5d147ab4zad37z4f6bzac51z32a08efeaa51
Xia, Q., Chen, Y., Shen, P., Gong, J., Lu, F.-E., & Chen, H. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.121676
Visker, J. R., Tseliou, E., Drosatos, K., Wever-Pinzon, O., Holland, W., & Drakos, S. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10626-2
Small-molecule inhibition of the deadenylase CNOT6L as a strategy of obesity treatment
Zhang, H., Zhao, J., Li, Y., Yuan, M., Lei, W., & Yang, S.-Y. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.04.008
When Fat Goes Astray: Your Liver and Pancreas Get Into Trouble
Chen, Y., Ding, L., Zhao, S., Wang, W. B., Zhong, J., & Yan, Q. (2026) · Portal hypertension & cirrhosis · doi:10.1002/poh2.70049
Novel Pharmacological and Nanotechnology-Based Therapeutic Strategies for MASLD
Villaseñor-Tapia, E. C., Franco-Acevedo, A., Rosas-Campos, R., & Armendáriz‐Borunda, J. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18050584
Zhang, C., & Yang, M. (2026) · World Journal of Hepatology · doi:10.4254/wjh.120178
Yu, L.-Y., & Zhang, X. (2026) · World Journal of Hepatology · doi:10.4254/wjh.117543
Naqash, M., Tariq, A., Shayan, S., Sargani, S. M., Raza, M. A., Khan, N., Balouch, A., Usama, R. M., & Ahmed, K. A. H. M. (2026) · International Journal of Hepatology · doi:10.1155/ijh/7391450
Peptide hormone-based combinational pharmacotherapies for chronic metabolic diseases
Chui, Z. S. W., Xue, Y., Wu, X., & Xu, A. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100150
The Biological Clock–Mitochondria Axis in the Liver: From Molecular Mechanisms to Metabolic Disease
Manuti, V., Murgo, E., Saponaro, A. A., Sfregola, U., Sangineto, M., Villani, R., Serviddio, G., Mazzoccoli, G., & Colangelo, T. (2026) · Biology · doi:10.3390/biology15141197
Leung, H.-K., Tan, G.-J., Wong, W., Khamis, F., Zain, S. M., & Chan, W. (2026) · Hepatoma Research · doi:10.20517/2394-5079.2026.20
Beneficial Hepatokines in MASLD/MASH: Therapeutic Potentials and Drug Delivery Challenges
Amatya, R., Min, K. A., & Shin, M. C. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27167118
Upcoming therapies for steatotic liver disease: Translating breakthroughs into clinical practice
Newsome, P. N., & Ajaz, S. (2026) · Journal of Internal Medicine · doi:10.1111/joim.70143 · Cited by 1
Exerkine-Mediated Inter-Organ Crosstalk and Translational Perspectives in Metabolic Diseases
Zhou, B., Zhang, S., Zhang, Z., Ran, S., Guo, H., Wang, S., & Meng, H. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00752-1
Akanbi, A., Bridle, K. R., & Crawford, D. H. (2026) · Bioscience Reports · doi:10.1042/bsr20250106
Boutari, C., Charalampidis, K., Sideras, L., Sinakos, E., & Goulis, I. (2026) · Life · doi:10.3390/life16101656
Taigade, S., Parab, S. B., & Doshi, G. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103390
Research Advances in the FGFR Signaling Axis in Hepatic Fibrosis
万, 良. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.16103343
BindingDB (2021) · UC San Diego · doi:10.7270/q2dj5jxg
Biological functions and emerging interplay of FGF21 and GDF15 in metabolic diseases and aging
Salmón‐Gómez, L., Keipert, S., Catalán, V., Rodrı́guez, A., Becerril, S., Frühbeck, G., & Gómez‐Ambrosi, J. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00627-w
Metadata
- Authors
- Sanyal, A., Charles, E. D., Neuschwander-Tetri, B. A., Loomba, R., Harrison, S. A., Abdelmalek, M. F., Lawitz, E. J., Halegoua-DeMarzio, D., Kundu, S., Noviello, S., Luo, Y., & Christian, R.
- Affiliations
- Virginia Commonwealth University (US)
- Bristol-Myers Squibb (United States) (US)
- University of California San Diego (US)
- Pinnacle Clinical Research (US)
- Duke University (US)
- The University of Texas at San Antonio Health Science Center (US)
- Thomas Jefferson University (US)
- Corresponding author
- Charles, Edgar D
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2018-12
- Volume
- 392
- Issue
- 10165
- Pages
- 2705-2717
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2905440332
- Cited by
- 550
- References
- 43
- Citations by year
- 2026: 40 · 2025: 52 · 2024: 87 · 2023: 82 · 2022: 76 · 2021: 83 · 2020: 91 · 2019: 36 · 2018: 1
- FWCI
- 41.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- PEGylation, nonalcoholic steatohepatitis, hepatic fat fraction, liver fibrosis, obesity, type 2 diabetes, drug safety, drug efficacy, subcutaneous injection, liver disease treatment
- MeSH terms
- Adult, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Administration Schedule, Female, Fibroblast Growth Factors, Humans, Injections, Subcutaneous, Male, Middle Aged, Obesity, Polyethylene Glycols, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
